Learn more about how our research and work with health care stakeholders drove health policy conversations forward last year.
NPC's Dr. Robert W. Dubois says we need to ask, “How can we best spend our health care dollars to benefit patients?”
How is high-quality, real-world evidence being generated, accepted and used to inform decision-making?
Is the value of medicines being recognized as an integral component of care?
What can we do to ensure patients have meaningful access to appropriate medications?
How can the health care system support biopharmaceutical innovation that improves patients’ lives?
New research from Tufts Medical Center and the National Pharmaceutical Council indicates that patient access to therapies depends on factors other than cost and clinical benefit.
Join NPC for a webinar highlighting its recently published paper examining the disconnect between the short-term budget impact of a treatment and its downstream effects on payers and society.
The National Pharmaceutical Council welcomed four companies, AstraZeneca, Gilead Sciences, Horizon Pharma and Spark Therapeutics, as the newest members of the health care research organization.